Last Updated on October 6, 2024 by The Health Master
DCGI issued alert: Falsified GLP-1-RA diabetes management drugs
In a recent development, the DCGI issued alert concerning suspected counterfeit versions of Glucagon-like peptide 1 receptor agonist (GLP-1-RA) products.
These pharmaceuticals are crucial in the management of diabetes type II and are also known for their role in weight loss.
The alert comes on the heels of a communication from the World Health Organization (WHO) regarding a safety threat posed by falsified versions of these drugs that have infiltrated the market.
The Nature of GLP-1-RA Products and the Concerns
GLP-1-RA, a notable class of pharmaceuticals, holds a dual significance as it not only aids in the management of diabetes type II but is also recognized for its potential in weight loss.
Marketed under diverse brand names across the globe, these products have gained substantial traction.
However, the emergence of counterfeit versions has cast a shadow of concern over their authenticity and efficacy.
DCGI issued alert: Key Takeaways
The Drugs Controller General (India), Dr. Rajeev Singh Raghuvanshi, has taken a proactive approach in addressing this alarming situation.
With this alert, DCGI has strongly advised all Drug Controllers in the States and Union Territories, as well as the zonal and sub-zonal offices of the Central Drugs Standard Control Organisation (CDSCO), to exercise heightened vigilance over the movement, sale, distribution, and stock of these drug products within the market.
This includes taking the following actions:
- Conducting thorough monitoring and surveillance of these products
- Drawing samples for meticulous testing
- Initiating necessary actions as per the regulations stipulated in the Drugs and Cosmetics Act and its accompanying rules.
Advice to Healthcare Professionals and Consumers
As part of its comprehensive approach, the DCGI issued alert / vital advisory to doctors and healthcare professionals.
They are urged to exercise caution when prescribing GLP-1-RA products, considering alternative treatments if necessary.
Moreover, doctors are encouraged to educate their patients about the importance of reporting any adverse reactions resulting from the use of these products.
This proactive measure aims to safeguard patient well-being and enhance the collection of valuable safety data.
Empowering Consumers and Patients
For consumers and patients, the drug regulatory authority emphasizes the significance of sourcing these medical products solely from authorized and reputable sources.
By doing so, consumers can mitigate the risks associated with counterfeit products and ensure the authenticity and efficacy of their treatments.
This directive underscores the importance of obtaining medical products from recognized channels and retaining proper purchase documentation.
Global Perspective and WHO’s Concerns
WHO, through its Threat Assessment No.2/2023, has highlighted a recent surge in demand for GLP-1-RA products designed to manage diabetes type II and facilitate weight loss.
The organization has noted a disturbing increase in the prevalence of falsified GLP-1 receptor agonists.
This rise in counterfeit products is further exacerbated by the surge in online information advocating the use of GLP-1-RA products for weight loss.
This trend has led to risky procurement behaviors, potentially exposing consumers to unregulated outlets including social media platforms.
Market Insights and Growth Projection
Market research and consulting firm Mordor Intelligence has provided valuable insights into the global market for GLP-1 agonists.
Estimated at $11.87 billion in 2023, this market is projected to witness growth, reaching $12.55 billion by 2028, with an annual growth rate of 1.12 percent.
This market expansion underscores the significance of these pharmaceuticals in managing diabetes type II and promoting weight loss.
In conclusion, the emergence of falsified GLP-1-RA products in the market has prompted a swift response from regulatory authorities and healthcare professionals alike.
By staying vigilant, sourcing from authorized channels, and reporting adverse reactions, patients can contribute to safer and more effective diabetes management strategies.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model, to rewrite and present the news / article in a unique format.
DCGI asks manufacturers: Not to submit same batch of cough syrup to multiple Laboratories
DCGI gives approval to import heart failure drug
DCGI plans unified Online Portal for Drug Quality and Patient Safety
Drug alert: DCGI issues drug alert on usage of cough and cold medicine
DCGI gives approval for Dupilumab to treat Atopic Dermatitis
Govt collaborates with Pharma Industry to lower prices of Rare Disease Medicines
Procedural lapses flagged at Aurobindo Pharma by USFDA: Telangana
USFDA gives nod for Potassium Chloride for Injection Concentrate
NPPA changes to Guidelines allowing Manufacturers shift for Approved Formulations
USFDA gives nod for Bromfenac Ophthalmic Solution, Metoprolol Tablets
Pharma Company Manager arrested for supplying Banned Drugs
The Controversy Surrounding Generic Drug Prescription
Inter-Ministry Coordination For Medical Devices Industry: A Critical Examination
USFDA gives approval for Doxycycline Hyclate delayed-release Tablets
Equipment and Instruments: Maintenance, difference and importance in the Pharma Industry
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
